Direxion Daily Phrmctcl&MdclBl3XShrsETF (PILL)
18.33
+0.62 +3.51%
NYSE Arca
Dec 6, 20:00
Delayed 2m
USD
Key Stats
| Expense Ratio | 0.99% |
| Total Assets Under Management | 11.03M |
| Share Class Assets Under Management | 11.03M |
| 30-Day Average Daily Volume | 31243.97 |
| Net Asset Value | 18.39 |
| Discount or Premium to NAV | -0.31% |
| Turnover Ratio | 152.0% |
| 1 Year Fund Level Flows | 6.654M |
View All PILL News
News
-
WireHeadlineTime (ET)
-
SA Breaking News11/22 16:55
-
SA Breaking News11/01 16:54
-
SA Breaking News10/18 16:35
-
SA Breaking News10/03 10:09
-
PR Newswire05/31 18:18
-
SA Breaking News04/26 16:30
-
SA Breaking News10/25 14:32
-
SA Breaking News08/24 04:46
Performance & Returns
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 22.75% | 22.99% | -- | -- |
| 3M | 44.08% | 44.31% | -- | -- |
| 6M | 11.95% | 12.33% | -- | -- |
| YTD | -13.48% | -14.23% | -- | -- |
| 1Y | -34.46% | -34.66% | -- | -- |
| 3Y | -- | -- | -- | -- |
| 5Y | -- | -- | -- | -- |
| 10Y | -- | -- | -- | -- |
| 15Y | -- | -- | -- | -- |
| 20Y | -- | -- | -- | -- |
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 1.31% | 19.44% | 18.12% |
| Stock | 98.69% | 98.69% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
Region Exposure
| Americas | 95.46% |
| North America | 95.46% |
| Latin America | 0.00% |
| Greater Europe | 3.56% |
| United Kingdom | 3.56% |
| Europe Developed | 0.00% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.00% |
| Greater Asia | 0.98% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.98% |
| Asia Emerging | 0.00% |
| Market Classification | |
| % Developed Markets | 100.0% |
| % Emerging Markets | 0.00% |
Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.00% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 100.0% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.00% |
| Utilities | 0.00% |
Stock Market Capitalization
| Giant | 22.03% |
| Large | 8.67% |
| Medium | 31.43% |
| Small | 33.66% |
| Micro | 4.22% |
Stock Style Exposure
| Large Cap Value | 13.33% |
| Large Cap Blend | 13.57% |
| Large Cap Growth | 4.14% |
| Mid Cap Value | 7.40% |
| Mid Cap Blend | 15.16% |
| Mid Cap Growth | 9.22% |
| Small Cap Value | 6.23% |
| Small Cap Blend | 9.62% |
| Small Cap Growth | 21.33% |
View More Holdings
As of Nov. 30, 2019
Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| -- | Future on SPDR® S&P Pharmaceuticals ETF Dec49 | 19.65% | -- | -- |
| RETA | Reata Pharmaceuticals Inc A | 3.97% | 199.32 | -0.12% |
| HZNP | Horizon Therapeutics PLC | 3.94% | 32.23 | +1.16% |
| BMY | Bristol-Myers Squibb Company | 3.65% | 59.95 | +0.79% |
| JAZZ | Jazz Pharmaceuticals PLC | 3.64% | 149.46 | +0.92% |
| AGN | Allergan PLC | 3.53% | 186.37 | +0.16% |
| LLY | Eli Lilly and Co | 3.35% | 119.64 | -0.11% |
| MRK | Merck & Co Inc | 3.34% | 88.85 | +0.11% |
| JNJ | Johnson & Johnson | 3.33% | 140.38 | +0.59% |
| PFE | Pfizer Inc | 3.31% | 38.29 | +0.68% |
Advertisement
Basic Info
| Investment Strategy | |
|---|---|
| The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments and securities of the index, ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. | |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Alternative |
| Broad Category | Alternative |
| Category Name | Trading--Leveraged Equity |
| Prospectus Objective | Growth and Income |
| Fund Owner Firm Name | Direxion Funds |
| Benchmark Index | |
| S&P Pharms Select Industry TR USD | 100.0% |
| Reports | |
| One Page Report | Download |
Manager Info
| Name | Tenure |
|---|---|
| Paul Brigandi | 2.04 yrs |
| Tony Ng | 2.04 yrs |
Net Fund Flows
| 1M | 0.00 |
| 3M | -8.148M |
| 6M | -2.427M |
| YTD | 6.654M |
| 1Y | 6.654M |
| 3Y | -- |
| 5Y | -- |
| 10Y | -- |
Risk Info
| Beta (5Y) | -- |
| Max Drawdown (All) | 69.65% |
| Historical Sharpe Ratio (10Y) | -- |
| Historical Sortino (All) | -0.0993 |
| 30-Day Rolling Volatility | 51.41% |
| Daily Value at Risk (VaR) 1% (All) | 9.25% |
| Monthly Value at Risk (VaR) 1% (All) | 30.49% |
Fundamentals
| Dividend Yield TTM (12-6-19) | 1.06% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 23.83 |
| Weighted Average Price to Sales Ratio | 2.888 |
| Weighted Average Price to Book Ratio | 3.060 |
| Weighted Median ROE | 8.50% |
| Weighted Median ROA | -6.53% |
| Forecasted Dividend Yield | 0.79% |
| Forecasted PE Ratio | 11.15 |
| Forecasted Price to Sales Ratio | 2.465 |
| Forecasted Price to Book Ratio | 1.740 |
| Number of Holdings | 46 |
Growth Estimates
| Forecasted 5 Yr Earnings Growth | 7.78% |
| Forecasted Book Value Growth | 7.94% |
| Forecasted Cash Flow Growth | 0.61% |
| Forecasted Earnings Growth | 27.08% |
| Forecasted Revenue Growth | 0.35% |
Attributes
| Key Dates | |
|---|---|
| Inception Date | 11/15/2017 |
| Termination Date | |
| Last Annual Report Date | 10/31/2018 |
| Last Prospectus Date | 2/28/2019 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | Yes |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
Advertisement
